Document is current

Article History

Received: 5 June 2023

Accepted: 5 October 2023

First Online: 6 November 2023

Declarations

:

: Ethics approval was granted from the Research Ethics Board at the University of British Columbia (UBC C&W number H19-04044).

: Not applicable.

: The other authors declare that they have no competing interests. ESC has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Miravo, Medexus, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma, AstraZeneca, ALK; is a member of the healthcare advisory board for Food Allergy Canada; and was co-lead of the CSACI oral immunotherapy guidelines. JY received speaking honoraria from UBC CPD, Sanofi, AstraZeneca, Pfizer, Stallergenes Greer, Novartis, Pediapharm, Medexus Pharma. She has served on advisory/consultancy committees for Sanofi, Pfizer, HealthLinkBc, Stallergenes Greer, and LEO Pharma. TV has served on advisory boards and received honoraria from Aralez, Bausch Health, and Pfizer. EA served on the Healthcare advisory board, and Food Allergy Canada. She received moderator/speaker fees from Novartis, GSK, and AstraZeneca. RM was a moderator/speaker for Astra Zeneca, Pediapharm, and Novartis. He has been on advisory boards for Sanofi, and ALK.